Show
Sort by
-
The phase 2 CARTITUDE-2 trial : updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)
-
Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation
-
The treatment of multiple myeloma in an era of precision medicine
-
- Conference Paper
- C3
- open access
Proteasome inhibition by carfilzomib impairs terminal erythroid maturation and causes reticulocytosis in patients with multiple myeloma
-
- Journal Article
- A1
- open access
Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes
-
Concise review : treatment of multiple myeloma in the very elderly : how do novel agents fit in?